REGULATORY
Oculomucocutaneous Syndrome, Erythema Multiforme Added to ADR List for Halaven
The Ministry of Health, Labor and Welfare issued a drug safety bulletin on March 15, notifying physicians that oculomucocutaneous syndrome and erythema multiforme have been added to the list of clinically significant adverse drug reactions (ADRs) in the labeling for…
To read the full story
Related Article
- Add Rhabdomyolysis to Nexium Label: MHLW
February 17, 2016
- PMDA Reviewing Nexium for Risk of Rhabdomyolysis
January 25, 2016
REGULATORY
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
- 3 Label Expansions Get NHI Coverage on Public Knowledge Pathway
July 29, 2026
- No Cap on FY2027 Budget Requests under Growth Investment Scheme: MOF
July 29, 2026
- Japan Panel Green-Lights GSK’s Hep B Drug, Brinsupri, Hyrnuo
July 28, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





